Lowest Price Guaranteed From USD 1,899
Published
January 2023
Slides
198
View Count
1916
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
Digital therapeutics are clinically validated solutions that are delivered as applications, software and online programs, demonstrating the capability to facilitate positive outcomes when employed in the management of clinical conditions. These therapeutics are designed to engage patients in personalized treatment or disease prevention programs, through mediating behavioral or psychological modifications. The primary benefits of digital therapeutics include reduction of treatment related costs, generation and maintenance of personalized health data, reduction in stress amongst healthcare professionals, and increase in the adherence to prescribed treatment regimens. In addition, these digital health solutions provide motivational support and inculcate healthy lifestyle changes in the target patient population. Currently, a wide variety of digital health applications and intuitive software are available for the aforementioned purposes. In fact, the COVID-19 pandemic has created a significant demand for remote healthcare solutions. Amidst other alternatives, digital therapeutics have emerged as a promising option since these can be employed as preventive or curative digital solutions for managing diverse target indications. A recent survey highlighted that the percentage of patients adopting digital therapeutics in the US rose from 4.7% to 18%, post the pandemic outbreak, resulting in an increased prescription rate of such therapeutics. Presently, there are more than 40 USFDA approved digital therapeutic solutions available in the market, including apps, software and devices, for the management of numerous therapeutic areas, such as mental health disorders, substance use disorders and reproductive health. It is worth noting that reSET, developed by Pear Therapeutics, was the first prescription digital therapeutics that received the USFDA approval in 2017. The application can be used as a method of opioid replacement therapy, increasing a patient's abstinence from substances of abuse during the treatment and enhancing the outpatient treatment program retention.
Owing to the increased adoption rate of digital solutions and rise in the demand for remote healthcare services, the companies involved in the digital therapeutics domain have witnessed a surge in the investment activity, with capital investments worth more than USD 9 billion. According to the recent trends, various digital therapeutic companies are engaged in providing personalized solutions, along with remote access to medical care facilities, including a health coach. Further, taking into consideration both the historical and contemporary scenarios, we believe that the digital therapeutics market presents lucrative investment opportunities for both short and long-term investors.
Scope of the Report
The Investor Series: Opportunities in the Digital Therapeutics Market (Focus on Need for Digital Therapeutics, Market Landscape of Innovators, Analysis of Product Offerings and Affiliated Value Propositions, Insights from Historical Funding Activity, Company Health Indexing, Financial Analysis of Key Public Ventures, Market Forecast and Opportunity Analysis, Insights from Publicly Disclosed Investor Exits and Key Acquisition Targets) report provides detailed information on the digital therapeutics market, covering the core and peripheral digital therapeutics solutions. It offers a technical and financial perspective on how the opportunity in this domain is likely to evolve, in terms of future business success, over the coming decade. The information in this report has been presented across multiple deliverables, featuring MS Excel sheets (some of which include interactive elements) and an MS PowerPoint deck, which summarizes the key takeaways from the project, and insights drawn from the curated data. The report features the following details:
One of the key objectives of the report was to identify the primary growth drivers and estimate the future growth opportunity associated within the digital therapeutics market, over the coming decades. We have provided informed estimates on the likely evolution of the market, during the period 2023-2035, based on various parameters, such as historical sales, target patient population, likely adoption rates and expected pricing. Our year wise projections of the current and forecasted opportunity within the digital therapeutics market have been further segmented across type of solution (standalone software application, combination offerings of software application + device, combination offerings of software application + AI support , combination offerings of software application + personal coach, combination offerings of software application + device + AI support , combination offerings of software application + device + personal coach and others), type of therapy (curative solutions and preventive solutions), therapeutic area (cardiovascular disorders, chronic pain, mental health problems, metabolic disorders, neurological disorders, respiratory disorders, sleep disorders, substance use disorders and others), and geographical regions (North America, Europe and Asia-Pacific and Rest of the World). In order to account for future uncertainties in the market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
EXCEL DELIVERABLE
Spreadsheet I includes details on the companies captured in the report, along with their respective products. It also features proprietary company health indexing analysis, value proposition analysis, insights from a detailed company competitiveness analysis and a list of industry stakeholders that were deemed to be likely targets for mergers / acquisitions, in the near future. The deliverable includes a summary dashboard, featuring interactive graphical representations of key insights generated from the data collated.
Spreadsheet II features a summary dashboard, including interactive graphical representations of some of the key insights generated related to the capital investments made in digital therapeutics domain (since 2011).
Spreadsheet III is a collection of multiple MS Excel sheets that provide summaries of insights generated from a detailed fundamental and technical financial analysis, of publicly listed ventures in the innovator companies’ dataset.
Spreadsheet IV offers our independent perspective on the various types of risks (namely operations-related risks, business-related risks, financial / asset-related risks, product / technology risks, and other risks) that the publicly listed ventures are presently exposed to; it includes a summary heat map representation that provides a pictorial perspective of the diversity and level of risks (as per our opinion), as well.
Spreadsheet V is a summary MS Excel dashboard, offering detailed graphical representations of the contemporary and future opportunity associated with the digital therapeutics domain.
Spreadsheet VI includes publicly available information on the investments made by selected investors in companies that are now publicly listed. Based on the data, we have offered a perspective on likely return on investments received by the mentioned investors.
POWERPOINT DELIVERABLE
Chapter 1 provides a brief summary of the content presented in the report, beginning with the need for digital therapeutics. It goes on to discuss some of the key benefits of these solutions and their advantages over the conventional therapies. Finally, the chapter provides an overview of the current scenario, offering a perspective on how, in light of recent funding activity, the market is likely to evolve over the coming years.
Chapter 2 and 3 feature brief (pictorial) summaries of the key objectives and approach used for data collection and analysis, in this study.
Chapter 4 features an executive summary of the key insights generated from the data and analytical outputs presented in the report.
Section I: Need for Digital Therapeutics and Innovators Landscape
Chapter 5 describes the current need for digital therapeutics, highlighting the key facts about the origin and development of digital therapeutics. It features information on the current areas of innovation, along with opinions of experts, describing various benefits of these therapies, and anticipated future challenges. It includes information on some of the key players that are engaged in this domain. The views presented in this chapter are backed by inputs from representatives from key stakeholder companies in this domain (as stated in publicly available articles and interview transcripts).
Chapter 6 focuses on some of the innovators (companies established on or after 2005) and features detailed analysis of the companies. It highlights important company related details, such as year of establishment, headquarters, company size, and type of venture.
Chapter 7 includes information on the various products and affiliated services offered by the companies captured in the report (listed in Chapter 6). It also features analysis based on number and types of products. Based on the insights and details presented in Chapter 6, we have developed a quantitative perspective on the relative health (based on basic company details, product details and financing activity) of the different innovator companies.
Chapter 8 offers an informed perspective on the apparent value proposition of the companies captured in the report (listed in Chapter 6). Based on multiple relevant inputs (as inferred from publicly disclosed value statements), namely outreach-related value offered, developer-related value, value to patients and product-related value, we developed an empirical framework to quantify the value proposition of a business.
Chapter 9 features a detailed company competitiveness analysis, offering a quantitative basis for comparing the developer of digital therapeutics captured in this report. It is worth mentioning that the analysis described in this section is based on a proprietary scoring criterion, which was informed via our company health indexing.
Section II Analysis of Investments
Chapter 10 offers insights from a detailed analysis of the funding and investment activity in this domain, since 2011. It includes financing category-wise trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the innovator companies discussed in the report.
Section III Financial Analysis and Assessment of Business Risks
Chapter 11 is modelled in the likeness of an equity research report. It features a review of the overall digital therapeutics market from a financial perspective and includes detailed fundamental (insights from the balance sheet, and key financial ratios) and technical analyses (insights from historical and recent stock price variations, and analysis using popular stock performance indicators) of financial data of nine of the publicly listed companies within the innovator landscape dataset.
Chapter 12 includes detailed profiles of the public ventures engaged in the development of digital therapeutics. Each profile features a brief overview of the company, its insight from balance sheet (if available), details on its management team, a section on recent developments and key financial details (including company investment highlights, company fundamental and company technical analysis)
Chapter 13 includes a business risk analysis, offering insights encompassing several known categories of risk; these include operations-related risks, business-related risks, product / technology risks, financial / asset-related risks, and other risks.
Section IV Market Forecast and Opportunity Analysis
Chapter 14 features an insightful market forecast analysis, highlighting the estimated current and future size of the overall digital therapeutics market, till the year 2035. The opportunity has been segregated on the basis of type of solution (standalone software application, combination offerings of software application + device, combination offerings of software application + AI support , combination offerings of software application + personal coach, combination offerings of software application + device + AI support , combination offerings of software application + device + personal coach and others), type of therapy (curative solutions and preventive solutions), therapeutic area (cardiovascular disorders, chronic pain, mental health problems, metabolic disorders, neurological disorders, respiratory disorders, sleep disorders, substance use disorders and others) and geographical regions (North America, Europe, Asia-Pacific and Rest of the World.
Section V Analysis of Returns on Investment and Key Acquisition Targets
Chapter 15 includes case studies of instances where investors have exited various digital therapeutics-related ventures, offering insights on return on investments made (based on availability of data). The abovementioned estimates / details, offer a perspective on how past investments have paid off for investors as companies gradually went public, over time.
Chapter 16 offers insights from a proprietary analysis that leverages inputs from the startup health indexing and value proposition analysis (described in Section I), to offer qualitative recommendations on companies that are likely to be perceived as key acquisition targets.
Chapter 17 provides a pictorial summary of the overall project.
Chapter 18 is a set of appendices.
EXCEL DELIVERABLE
1. INNOVATORS AND PRODUCTS DATASET
1.1. Analysis Notes
1.2. Innovator Landscape
1.3. Product Landscape
1.4. Value Proposition
1.5. Key Acquisition Targets
1.6. AI – AVII Appendices
2. FUNDING AND INVESTMENT ANALYSIS
2.1. Analysis Notes
2.2. Summary Dashboard
2.3. Capital Investments in Digital Therapeutics
2.4 AI – AIV Appendices
3. FUNDAMENTAL AND TECHNICAL FINANCIAL ANALYSIS
The information presented in this analysis is spread across separate MS Excel sheets, which provide information on key financial parameters and competitive insights based on historical and prevalent trends.
4. BUSINESS RISK ANALYSIS
4.1. Analysis Notes
4.2. Business Risk Data
4.3. AI – AVII Appendices
5. MARKET FORECAST AND OPPORTUNITY ANALYSIS
5.1. Analysis Notes
5.2. Market Forecast and Opportunity Analysis: Summary
5.3. Market Forecast and Opportunity Analysis: Base Scenario
5.4. Market Forecast and Opportunity Analysis: Conservative Scenario
5.5. Market Forecast and Opportunity Analysis: Optimistic Scenario
6. RETURN ON INVESTMENT
6.1. Analysis Notes
6.2. Estimated RoI for Investors in Company A
6.3. Estimated RoI for Investors in Company B
6.4. Estimated RoI for Investors in Company C
POWERPOINT DELIVERABLE
1. CONTEXT
2. PROJECT APPROACH
3. PROJECT OBJECTIVES
4. EXECUTIVE SUMMARY
Section I: Need for Digital Therapeutics and Innovators Landscape
5. THE DIGITAL THERAPEUTICS MARKET
5.1. Overview
5.2. Historical Milestones
5.3. Key Types of Solutions
5.4. Key Strategic Initiatives
5.5. Key Concepts, Marketed Products and Challenges
6. DIGITAL THERAPEUTICS: INNOVATOR LANDSCAPE
6.1. Methodology
6.2. Innovators in the Digital Therapeutics Market
6.3. Analysis of Competitive Landscape
6.4. Conclusion
7. DIGITAL THERAPEUTICS: PRODUCT LANDSCAPE AND COMPANY HEALTH INDEXING
7.1. List of Digital Therapeutics
7.2. Analysis of Product Landscape
7.3. Health Indexing Methodology
7.4. Company Health Indexing
8. VALUE PROPOSITION ANALYSIS
8.1. Overview and Methodology
8.2. Outreach-related Value
8.3. Developer Value
8.4. Product-related Value
8.5. Value to Patients
8.6. Concluding Remarks
9. COMPANY COMPETITIVENESS ANALYSIS
9.1. Overview and Methodology
9.2. Company Competitiveness Analysis
Section II Analysis of Investments
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Overview
10.2. Analysis by Type of Funding
10.3. Analysis by Geography and Most Active Players
10.4. Analysis of Trends Across Various Funding Categories
10.5. Summary of Funding and Investments
Section III Financial Analysis and Assessment of Business Risks
11. FINANCIAL ANALYSIS OF PUBLIC VENTURES
11.1. Fundamental Financial Analysis Overview
11.2. Financial Ratios (Interpretation Guide)
11.3. Case Study 1
11.4. Technical Financial Analysis Overview
11.5. Technical Indicators (Interpretation Guide)
11.6. Case Study 2
12. COMPANY PROFILES OF PUBLIC VENTURES
12.1 Akili Interactive
12.1.1. Key Highlights
12.1.1.1. Company Details
12.1.1.1. Company Overview
12.1.1.3. Insights from Balance Sheet
12.1.1.4. Management Team
12.1.1.5. Recent Developments
12.1.2. Key Financial Details
12.1.2.1. Company Investments
12.1.2.2. Company Fundamentals
12.1.2.3. Company Technicals
12.2. Better Therapeutics
12.2.1. Key Highlights
12.2.1.1. Company Details
12.2.1.1. Company Overview
12.2.1.3. Insights from Balance Sheet
12.2.1.4. Management Team
12.2.1.5. Recent Developments
12.2.2 Key Financial Details
12.2.2.1. Company Investments
12.2.2.2. Company Fundamentals
12.2.2.3. Company Technicals
12.3. Brain+
12.3.1. Key Highlights
12.3.1.1. Company Details
12.3.1.1. Company Overview
12.3.1.3. Insights from Balance Sheet
12.3.1.4. Management Team
12.3.1.5. Recent Developments
12.3.2. Key Financial Details
12.3.2.1. Company Investments
12.3.2.2. Company Fundamentals
12.3.2.3. Company Technicals
12.4. Dario Health
12.4.1. Key Highlights
12.4.1.1. Company Details
12.4.1.1. Company Overview
12.4.1.3. Insights from Balance Sheet
12.4.1.4. Management Team
12.4.1.5. Recent Developments
12.4.2 Key Financial Details
12.4.2.1. Company Investments
12.4.2.2. Company Fundamentals
12.4.2.3. Company Technicals
12.5. Ehave
12.5.1. Key Highlights
12.5.1.1. Company Details
12.5.1.1. Company Overview
12.5.1.3. Insights from Balance Sheet
12.5.1.4. Management Team
12.5.1.5. Recent Developments
12.5.2. Key Financial Details
12.5.2.1. Company Investments
12.5.2.2. Company Fundamentals
12.5.2.3. Company Technicals
12.6. Mindcure
12.6.1. Key Highlights
12.6.1.1. Company Details
12.6.1.1. Company Overview
12.6.1.3. Insights from Balance Sheet
12.6.1.4. Management Team
12.6.1.5. Recent Developments
12.6.2. Key Financial Details
12.6.2.1. Company Investments
12.6.2.2. Company Fundamentals
12.6.2.3. Company Technicals
12.7. Newtopia
12.7.1. Key Highlights
12.7.1.1. Company Details
12.7.1.1. Company Overview
12.7.1.3. Insights from Balance Sheet
12.7.1.4. Management Team
12.7.1.5. Recent Developments
12.7.2. Key Financial Details
12.7.2.1. Company Investments
12.7.2.2. Company Fundamentals
12.7.2.3. Company Technicals
12.8. Pear Therapeutics
12.8.1. Key Highlights
12.8.1.1. Company Details
12.8.1.1. Company Overview
12.8.1.3. Insights from Balance Sheet
12.8.1.4. Management Team
12.8.1.5. Recent Developments
12.8.2. Key Financial Details
12.8.2.1. Company Investments
12.8.2.2. Company Fundamentals
12.8.2.3. Company Technicals
12.9. Sharecare
12.9.1. Key Highlights
12.9.1.1. Company Details
12.9.1.1. Company Overview
12.9.1.3. Insights from Balance Sheet
12.9.1.4. Management Team
12.9.1.5. Recent Developments
12.9.2 Key Financial Details
12.9.2.1. Company Investments
12.9.2.2. Company Fundamentals
12.9.2.3. Company Technicals
13. BUSINESS RISK ANALYSIS
13.1. Overview and Methodology
13.2. Operations-related Risks
13.3. Business-related Risks
13.4. Financial / Asset-related Risks
13.5. Product / Technology Risks
13.6. Other Risks
13.7. Business Risk Summary
Section IV Market Forecast and Opportunity Analysis
14. MARKET FORECAST
14.1. Overview and Methodology
14.2. Global Digital Therapeutics Market, 2023-2035
14.3. Distribution Across Key Market Segments
14.3.1. Digital Therapeutics Market: Distribution by Type of Solution, 2023 and 2035
14.3.1.1. Digital Therapeutics Market for Standalone Software Application, 2023-2035
14.3.1.2. Digital Therapeutics Market for Combination Offerings (Software Application + Device), 2023-2035
14.3.1.3. Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), 2023-2035
14.3.1.4. Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), 2023-2035
14.3.1.5. Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), 2023-2035
14.3.1.6. Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), 2023-2035
14.3.1.7. Digital Therapeutics Market for Other Types of Solutions, 2023-2035
14.3.2. Digital Therapeutics Market: Distribution by Type of Therapy, 2023 and 2035
14.3.2.1. Digital Therapeutics Market for Curative Therapy, 2023-2035
14.3.2.2. Digital Therapeutics Market for Preventive Therapy, 2023-2035
14.3.3. Digital Therapeutics Market: Distribution by Therapeutic Area, 2023 and 2035
14.3.3.1. Digital Therapeutics Market for Cardiovascular Disorders, 2023-2035
14.3.3.2. Digital Therapeutics Market for Chronic Pain, 2023-2035
14.3.3.3 Digital Therapeutics Market for Mental Health Problems, 2023-2035
14.3.3.4 Digital Therapeutics Market for Metabolic Disorders, 2023-2035
14.3.3.5 Digital Therapeutics Market for Neurological Disorders, 2023-2035
14.3.3.6 Digital Therapeutics Market for Respiratory Disorders, 2023-2035
14.3.3.7 Digital Therapeutics Market for Sleep Disorders, 2023-2035
14.3.3.8 Digital Therapeutics Market for Substance Use Disorders, 2023-2035
14.3.3.9 Digital Therapeutics Market for Other Disorders, 2023-2035
14.3.4. Digital Therapeutics Market: Distribution by Geographical Regions, 2023 and 2035
14.3.4.1. Digital Therapeutics Market in North America, 2023-2035
14.3.4.2. Digital Therapeutics Market in Europe, 2023-2035
14.3.4.3. Digital Therapeutics Market in Asia-Pacific and Rest of the World, 2023-2035
Section V Analysis of Returns on Investment and Key Acquisition Targets
15. ANALYSIS OF RETURNS ON INVESTMENT
15.1. Overview and Methodology
15.2. Case Studies
16. KEY ACQUISITION TARGETS
16.1. Overview
16.2. List of Key Acquisition Targets
17. CONCLUSION
18. APPENDICES
Figure 5.1. Digital Therapeutics: Key Definitions and Background
Figure 5.2. Digital Therapeutics: Key Historical Milestones
Figure 5.3. Digital Therapeutics: Types of Solutions and Key Industry Players
Figure 5.4. Digital Therapeutics: Key Strategic Initiatives
Figure 5.5 Digital Therapeutics: Key Marketed Products and Challenges
Figure 6.1. Innovator Landscape: Distribution by Year of Establishment
Figure 6.2. Innovator Landscape: Distribution by Type of Venture
Figure 6.3. Innovator Landscape: Distribution by Company Size
Figure 6.4. Innovator Landscape: Distribution by Geography
Figure 7.1. Product Landscape: Distribution of Innovators by Number of Products
Figure 7.2. Product Landscape: Distribution by Type of Therapy
Figure 7.3. Product Landscape: Distribution of Products by Status of Development
Figure 7.4. Product Landscape: Distribution of Products by Type of Solution
Figure 7.5. Product Landscape: Distribution of Innovators by Therapeutic Area
Figure 8.1. Companies Offering Outreach-Related Value: Distribution of Companies by Value Offered and Experience
Figure 8.2. Companies Offering Outreach-Related Value: Analysis of Companies Offering Very High Value
Figure 8.3. Companies Offering Developer Value: Distribution of Companies by Value Offered and Experience
Figure 8.4. Companies Offering Developer Value: Analysis of Companies Offering Very High Value (2007-2013)
Figure 8.5. Companies Offering Developer Value: Analysis of Companies Offering Very High Value (2014 Onwards)
Figure 8.6. Companies Offering Product-related Value: Distribution of Companies by Value Offered and Experience
Figure 8.7. Companies Offering Product-related Value: Analysis of Companies Offering Very High Value
Figure 8.8. Companies Offering Value to Patients: Distribution of Companies by Value Offered and Experience
Figure 8.9. Companies Offering Value to Patients: Analysis of Companies Offering Very High Value
Figure 9.1. Competitiveness Analysis: Large Companies based in North America (Peer Group I)
Figure 9.2. Competitiveness Analysis: Mid-sized Companies based in North America (Peer Group II)
Figure 9.3. Competitiveness Analysis: Small Companies based in North America (Peer Group III)
Figure 9.4. Competitiveness Analysis: Very Small Companies based in North America (Peer Group IV)
Figure 9.5. Competitiveness Analysis: Large and Mid-sized Companies based in Europe (Peer Group V)
Figure 9.6. Competitiveness Analysis: Small Companies based in Europe (Peer Group VI)
Figure 9.7. Competitiveness Analysis: Very Small Companies based in Europe (Peer Group VII)
Figure 9.8. Competitiveness Analysis: Mid-sized Companies based in Asia-Pacific and Rest of the World (Peer Group VIII)
Figure 9.9. Competitiveness Analysis: Small Companies based in Asia-Pacific and Rest of the World (Peer Group IX)
Figure 9.10. Competitiveness Analysis: Very Small Companies based in Asia-Pacific and Rest of the World (Peer Group X)
Figure 10.1. Funding and Investment Analysis: Year-wise Distribution of Funding Instances and Amount Invested (2011-2022)
Figure 10.2. Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 10.3. Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding
Figure 10.4. Funding and Investment Analysis: Geographical Distribution
Figure 10.5. Funding and Investment Analysis: Most Active Players (Number of Instances)
Figure 10.6. Funding and Investment Analysis: Most Active Players (By Amount Raised)
Figure 10.7. Awards / Grants: Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.8. Awards / Grants: Geographical Distribution by Amount Invested
Figure 10.9. Awards / Grants: Most Active Investors
Figure 10.10. Seed Funding: Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.11. Seed Funding: Geographical Distribution by Amount Invested
Figure 10.12. Seed Funding: Most Active Investors
Figure 10.13. Private Placements: Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.14. Private Placements: Geographical Distribution by Amount Invested
Figure 10.15. Private Placements: Most Active Investors
Figure 10.16. Debt Financing: Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.17. Debt Financing: Geographical Distribution by Amount Invested
Figure 10.18. Debt Financing: Most Active Investors
Figure 10.19. Venture (Series A): Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.20. Venture (Series A): Geographical Distribution by Amount Invested
Figure 10.21. Venture (Series A): Most Active Investors
Figure 10.22. Venture (Series B): Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.23. Venture (Series B): Geographical Distribution by Amount Invested
Figure 10.24. Venture (Series B): Most Active Investors
Figure 10.25. Venture (Series C): Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.26. Venture (Series C): Geographical Distribution by Amount Invested
Figure 10.27. Venture (Series C): Most Active Investors
Figure 10.28. Venture (Series D): Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.29. Venture (Series D): Geographical Distribution by Amount Invested
Figure 10.30. Venture (Series D): Most Active Investors
Figure 10.31. Venture (Series E, F, G and Unknown): Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.32. Venture (Series E, F, G and Unknown): Geographical Distribution by Amount Invested
Figure 10.33. Venture (Series E, F, G and Unknown): Most Active Investors
Figure 10.34. Public Offering: Year-wise Distribution of Funding Instances and Amount Invested (USD Million)
Figure 10.35. Public Offering: Geographical Distribution by Amount Invested
Figure 10.36. Public Offering: Most Active Investors
Figure 10.37. Capital Investments in Digital Therapeutics Company: Summary of Funding and Investments, 2011-2022
Figure 11.1. Fundamental Financial Analysis: Annual Revenues and Key Balance Sheet Parameter-related Trends
Figure 11.2. Fundamental Financial Analysis: Liquidity Ratios
Figure 11.3. Fundamental Financial Analysis: Financial & Business Risk Ratios and Turnover / Efficiency Ratios
Figure 11.4. Fundamental Financial Analysis: Profitability Ratios
Figure 11.5. Fundamental Financial Analysis: Market Value Ratios & Stability Ratios
Figure 11.6. Technical Financial Analysis: Stock Price (Candlestick Chart) and Volume Traded
Figure 11.7. Technical Financial Analysis: 5-Day Moving Average
Figure 11.8. Technical Financial Analysis: 10-Day Moving Average
Figure 11.9. Technical Financial Analysis: 50-Day Moving Average
Figure 11.10. Technical Financial Analysis: Bollinger Band®
Figure 11.11. Technical Financial Analysis: Relative Strength Index
Figure 11.12. Technical Financial Analysis: Commodity Channel Index
Figure 11.13. Technical Financial Analysis: MACD
Figure 11.14. Technical Financial Analysis: Williams’ R Analysis
Figure 11.15. Technical Financial Analysis: Average Directional Index (ADX)
Figure 12.1. Akili Interactive: Company Fundamentals
Figure 12.2. Akili Interactive: Trend of Stock Prices Since Initial Public Offering
Figure 12.3. Better Therapeutics: Company Fundamentals
Figure 12.4. Better Therapeutics: Trend of Stock Prices Since Initial Public Offering
Figure 12.5. Brain+: Company Fundamentals
Figure 12.6. Brain+: Trend of Stock Prices Since Initial Public Offering
Figure 12.7. Dario Health: Company Fundamentals
Figure 12.8. Dario Health: Trend of Stock Prices Since Initial Public Offering
Figure 12.9. Ehave: Company Fundamentals
Figure 12.10. Ehave: Trend of Stock Prices Since Initial Public Offering
Figure 12.11. Mindcure: Company Fundamentals
Figure 12.12. Mindcure: Trend of Stock Prices Since Initial Public Offering
Figure 12.13. Newtopia: Company Fundamentals
Figure 12.14. Newtopia: Trend of Stock Prices Since Initial Public Offering
Figure 12.15. Pear Therapeutics: Company Fundamentals
Figure 12.16. Pear Therapeutics: Trend of Stock Prices Since Initial Public Offering
Figure 12.17. Sharecare: Company Fundamentals
Figure 12.18. Sharecare: Trend of Stock Prices Since Initial Public Offering
Figure 13.1. Business Risk Analysis: Operations-related Risks
Figure 13.2. Business Risk Analysis: Business-related Risks
Figure 13.3. Business Risk Analysis: Financial / Asset-related Risks
Figure 13.4. Business Risk Analysis: Product / Technology Risks
Figure 13.5. Business Risk Analysis: Other Risks
Figure 13.6. Summary of Business Risk Analysis
Figure 14.1. Digital Therapeutics Market: Forecast, 2023-2035 (USD Million)
Figure 14.2. Digital Therapeutics Market: Distribution by Type of Solution, 2023 and 2035
Figure 14.3. Digital Therapeutics Market for Standalone Software Applications, 2023-2035 (USD Million)
Figure 14.4. Digital Therapeutics Market for Combination Offerings (Standalone Software Applications + Device), 2023-2035 (USD Million)
Figure 14.5. Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), 2023-2035 (USD Million)
Figure 14.6. Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), 2023-2035 (USD Million)
Figure 14.7. Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), 2023-2035 (USD Million)
Figure 14.8. Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), 2023-2035 (USD Million)
Figure 14.9. Digital Therapeutics Market for Other Types of Solutions, 2023-2035 (USD Million)
Figure 14.10. Digital Therapeutics Market: Distribution by Type of Therapy, 2023 and 2035
Figure 14.11 Digital Therapeutics Market for Curative Solutions, 2023-2035 (USD Million)
Figure 14.12 Digital Therapeutics Market for Preventive Solutions, 2023-2035 (USD Million)
Figure 14.13 Digital Therapeutics Market: Distribution by Therapeutic Area, 2023 and 2035
Figure 14.14 Digital Therapeutics Market for Cardiovascular Disorders, 2023-2035 (USD Million)
Figure 14.15 Digital Therapeutics Market for Pain Management, 2023-2035 (USD Million)
Figure 14.16 Digital Therapeutics Market for Mental Health Problems, 2023-2035 (USD Million)
Figure 14.17 Digital Therapeutics Market for Metabolic Disorders, 2023-2035 (USD Million)
Figure 14.18 Digital Therapeutics Market for Neurological Disorders, 2023-2035 (USD Million)
Figure 14.19 Digital Therapeutics Market for Respiratory Disorders, 2023-2035 (USD Million)
Figure 14.20 Digital Therapeutics Market for Sleep Disorders, 2023-2035 (USD Million)
Figure 14.21 Digital Therapeutics Market for Substance Use Disorders, 2023-2035 (USD Million)
Figure 14.22 Digital Therapeutics Market for Other Disorders, 2023-2035 (USD Million)
Figure 14.23 Digital Therapeutics Market: Distribution by Key Geographical Regions, 2023 and 2035
Figure 14.24 Digital Therapeutics Market in North America, 2023-2035 (USD Million)
Figure 14.25 Digital Therapeutics Market in Europe, 2023-2035 (USD Million)
Figure 14.26 Digital Therapeutics Market in Asia-Pacific and Rest of the World, 2023-2035 (USD Million)
Figure 16.1. Key Acquisition Targets: Comparison of Scores with Overall Dataset
Figure 16.2. Key Acquisition Targets: Comparison based on Qualifying Parameters (1/4)
Figure 16.3. Key Acquisition Targets: Comparison based on Qualifying Parameters (2/4)
Figure 16.4. Key Acquisition Targets: Comparison based on Qualifying Parameters (3/4)
Figure 16.5. Key Acquisition Targets: Comparison based on Qualifying Parameters (4/4)
Figure 17.1. Concluding Remarks: North America
Figure 17.2. Concluding Remarks: Europe
Figure 17.3. Concluding Remarks: Asia-Pacific and Rest of the World
Table 6.1. Key Innovators in the Digital Therapeutics Market
Table 7.1. Products Offered by Innovators in the Digital Therapeutics Market
Table 7.2. Company Health Indexing
Table 11.1. Fundamental Financial Analysis: List of Publicly Listed Digital Therapeutics Developers
Table 11.2. Technical Financial Analysis: List of Publicly Listed Digital Therapeutics Developers
Table 16.1 List of Digital Therapeutics Likely Acquisition Targets (Company Strength)
Table 16.2. List of Digital Therapeutics Likely Acquisition Targets (Value Proposition)
The following companies / institutes / government bodies and organizations have been mentioned in this report.
Source 1: https://www.digital-adoption.com/digital-adoption-healthcare-research/
Source 2: https://sdlcpartners.com/insights/what-is-digital-therapeutics/
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES